CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
TLC599drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02803307
NCT02803307Phase 2Completed
CompareCT.gov

A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee

Taiwan Liposome Company·interventional·Posted Jun 16, 2016·Updated May 6, 2022

In Brief

A Phase 2 clinical trial evaluating TLC599 for Osteoarthritis of the Knee. Completed, enrolled 40 participants across 3 sites.

Detailed Summary

This trial is a multi-site, randomized, open-label, parallel, and single-dose administration study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesTaiwan
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 16, 2016
Enrollment StartJun 1, 2015
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.0 years ago

Interventions

TLC599drug

Single dose via intra-articular injection